Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.
With the support of the Pamela and David Ott Fund and the John M. O'Quinn Foundation, The Pamela and David Ott Center of Excellence in Heritable Disorders of Connective Tissue and Ehlers-Danlos ...
Connective tissue diseases (CTDs) increase the risk for adverse maternal and fetal outcomes during pregnancy, with varying impacts across different CTD subtypes, according to study results published ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback